CytoDyn (CYDY) Free Cash Flow (2010 - 2026)
CytoDyn's (CYDY) quarterly Free Cash Flow came in at -$5.5 million in Q1 2026, down 11.36% YoY from -$6.2 million in Q1 2025, and down 26.87% on a QoQ basis from -$4.4 million in Q4 2025.
CytoDyn (CYDY) Free Cash Flow (2010 - 2026) Analysis & Trends
CytoDyn (CYDY) has 17 years of Free Cash Flow data on file, last reported at -$5.5 million in Q1 2026.
- Quarterly Free Cash Flow fell 11.36% year-over-year to -$5.5 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was -$18.0 million (down 278.41% YoY) and the FY2025 annual result came in at -$8.8 million, up 20.19% from the prior year.
- Free Cash Flow slipped to -$5.5 million in Q1 2026, from -$4.4 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $5.4 million in Q3 2024 to a low of -$11.1 million in Q3 2022.
- A 5-year average of -$4.4 million and a median of -$4.4 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow jumped 221.02% — and 2025, when it sank 243.21%.
- Tracing CYDY's Free Cash Flow over 5 years: stood at -$4.4 million in 2022, then jumped by 43.21% to -$2.5 million in 2023, then sank by 43.33% to -$3.6 million in 2024, then slipped by 21.31% to -$4.4 million in 2025, then fell by 26.87% to -$5.5 million in 2026.
- The last three Free Cash Flow figures came in at -$5.5 million (Q1 2026), -$4.4 million (Q4 2025), and -$2.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - | -5.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -5.52 Mn |
| Feb 28, 2026 | -5.52 Mn |
| Nov 30, 2025 | -4.35 Mn |
| Nov 30, 2025 | -4.35 Mn |
| Aug 31, 2025 | -2.45 Mn |
| Aug 31, 2025 | -2.45 Mn |
| May 31, 2025 | -5.66 Mn |
| May 31, 2025 | -5.66 Mn |
| Feb 28, 2025 | -4.96 Mn |
| Feb 28, 2025 | -4.96 Mn |
| Nov 30, 2024 | -3.59 Mn |
| Nov 30, 2024 | -3.59 Mn |
| Aug 31, 2024 | 5.44 Mn |
| Aug 31, 2024 | 5.44 Mn |
| May 31, 2024 | -1.65 Mn |
| May 31, 2024 | -1.65 Mn |
| Feb 29, 2024 | -2.34 Mn |
| Feb 29, 2024 | -2.34 Mn |
| Nov 30, 2023 | -2.50 Mn |
| Nov 30, 2023 | -2.50 Mn |